Feb 13, 2024 • 4:05pm EST Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
Jan 24, 2024 • 8:00am EST Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
Jan 23, 2024 • 8:00am EST Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism